Icatibant Gp Pharm (Icatibant)

Icatibant works by selectively and competitively blocking the bradykinin B2 receptor on vascular endothelial cells. This inhibition prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary drivers of the swelling seen in hereditary angioedema.

The prescribed dose is determined by the treating physician. In clinical practice, a single subcutaneous injection is administered at the onset of an HAE attack, and a second dose may be given if the swelling does not improve within a specified time frame. Exact dosing details are individualized.

Safety data for icatibant in pregnancy and lactation are limited. It is classified as pregnancy category unknown, so it should only be used when the potential benefit outweighs any possible risk to the fetus. Breastfeeding mothers should exercise caution, as excretion in milk has not been fully studied.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

The primary alternative to icatibant is C1‑inhibitor concentrate, which replaces the deficient protein. Icatibant acts downstream by blocking bradykinin receptors, offering a rapid, on‑demand subcutaneous option, whereas C1‑inhibitor is given intravenously and works by restoring the regulatory protein. Choice depends on clinical response, administration preferences and patient-specific factors.

Icatibant Gp Pharm must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, consult the supplier before use.

The medication is supplied as a sterile solution for subcutaneous injection. A healthcare professional or a trained patient injects the prescribed volume into the subcutaneous tissue, typically in the abdomen or thigh, using a pre‑filled syringe or autoinjector. Proper aseptic technique and site rotation are recommended.

Serious adverse events include anaphylaxis, severe angioedema affecting the face, lips or airway, and sudden hypotension. These reactions require immediate medical attention. Patients should be educated to recognize early signs and seek emergency care if they occur.

Icatibant should be avoided in individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients receiving ACE inhibitors, neprilysin inhibitors, or those with a history of severe angioedema unrelated to HAE, as the risk of adverse reactions may be higher.